Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-0105
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination ; volume:7 ; number:1 ; day:15 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
npj vaccines ; 7, Heft 1 (15.11.2022), 1-8, 12.2022
- Urheber
-
Byazrova, Maria G.
Astakhova, Ekaterina A.
Minnegalieva, Aygul R.
Sukhova, Maria M.
Mikhailov, Artem A.
Prilipov, Alexey G.
Gorchakov, Andrey A.
Filatov, Alexander V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-022-00566-x
- URN
-
urn:nbn:de:101:1-2023012809343628802686
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Byazrova, Maria G.
- Astakhova, Ekaterina A.
- Minnegalieva, Aygul R.
- Sukhova, Maria M.
- Mikhailov, Artem A.
- Prilipov, Alexey G.
- Gorchakov, Andrey A.
- Filatov, Alexander V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
A Compromise.
Compromise Rejected.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
A Compromise.
Compromise Rejected.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Comparing population-level humoral and cellular immunity to SARS-Cov-2 in Bangalore, India
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Vac
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
A Compromise.
Compromise Rejected.
No Compromise
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster